New Dual-Action drug targets Hard-to-Treat breast cancer

NCT ID NCT07121244

Recruiting now Disease control Sponsor: Radionetics Oncology Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 23 times

Summary

This early-stage study tests two related drugs in people with advanced hormone-receptor positive breast cancer that has spread or come back. The first drug (68Ga-R11228) helps doctors see tumors on a PET scan. The second drug (177Lu-R11228) delivers targeted radiation to kill cancer cells. The main goal is to check safety and find the right dose in about 62 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Indiana University Melvin and Bren Simon Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Melbourne Theranostic Innovation Centre (MTIC)
RECRUITING

Melbourne, Australia

Contact Email: •••••@•••••
United Theranostics
RECRUITING

Glen Burnie, Maryland, 21061, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
United Theranostics Princeton
RECRUITING

Princeton, New Jersey, 08540, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital Seidman Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Utah - Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER